HAE haemonetics.com: Forward P/S Multiple
Haemonetics Corporation (HAE) maintains a flawless reputation in the blood processing sector that supports revenue growth, where the 1.50 mark serves as a relevant indicator. Business stability is based on partnerships with plasma centers and quality control during the assembly of systems from external components. The forward P/S ratio demonstrates the current balance of supply and demand, helping to identify shifts in market momentum in a timely manner.
Metric breakdowns and analytics for Haemonetics Company (HAE)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Haemonetics Corporation|HAE - Long-Term Debt to Capital|Short-Term Debt to Equity Haemonetics Corporation|HAE - Company Debts|Debt to Book Value Haemonetics Company|HAE - Company Long-Term Loans and Borrowings|Company Short-Term Debts Haemonetics|Quick Liquidity haemonetics.com
- financial results and valuation multiples details:
HAE - Annual Net Income|Future Profit Haemonetics Corporation|HAE - P/E Multiple|Forward P/E Multiple Haemonetics Corp.|HAE - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haemonetics Company|HAE - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Haemonetics|HAE - Net earnings per share for the last 12 months|Quarterly EPS earnings growth haemonetics.com|HAE - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Haemonetics Corporation
- sales volume and revenue indicators:
Summary company analytics:Haemonetics (HAE)
This indicator reflects the asset's market value through the lens of expected sales, filtering out short-term noise from quotes by discounting future cash flows. By analyzing the forward P/S trend, an investor can assess the fair revenue premium for Haemonetics Corporation (HAE), considering its equipment's status as a global safety standard in transfusion medicine and the high margins derived from the company's monopoly positions.
Key competitors
Forward P/S Multiple DXCM (Dexcom)|Penumbra Inc (PEN) - Market Cap to Future Revenue Ratio|Novanta Corp - Forward P/S Multiple|INSP (Inspire Medical Systems Inc) - Market Cap to Projected Revenue|PRCT: Forward P/S Multiple|CNMD - Market Cap to Expected Sales Ratio|PLSE (Pulse Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple InMode Ltd (INMD)|Forward P/S Multiple PMI|Forward P/S Multiple Surmodics Inc. (SRDX)|Price-to-Projected Revenue Ratio Senseonics Holdings SENS|neuropace.com - Price-to-Projected Revenue Ratio|TCMD: Forward Price-to-Revenue Multiple|Forward Price to Sales SNWV (SANUWAVE Health)|OM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Electromed (ELMD)|Price-to-Projected Revenue Ratio LENSAR, Inc.|RCEL - Projected Price to Revenue|Forward Price-to-Revenue Multiple PROF (Profound Medical Corp.)|Forward P/S Multiple bairdmed.com (BDMD)|Forward P/S Multiple EDAP (EDAP TMS)|Market Cap to Expected Sales Ratio Apyx Medical Corp (APYX)|ICCM - Price-to-Projected Revenue Ratio|Future Price to Revenue LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoSorbents Corporation|SRTS (Sensus Healthcare Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Zynex Corp ZYXI|Price-to-Projected Revenue Ratio electroCore, Inc. (ECOR)|vicarioussurgical.com - Market Cap to Projected Revenue|Inspira Technologies - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICU (SeaStar Medical Holding Corporation)|IRIDEX Corp. - Forward P/S Multiple|Forward Price to Sales INBS (Intelligent Bio Solutions)|XAIR: Forward P/S Multiple|profusa.com (PFSA) - Forward P/S Multiple|SSKN (STRATA Skin Sciences Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio glucotrack.com GCTK|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Forward Price-to-Revenue Multiple Venus Concept Corporation VERO|Price-to-Projected Revenue Ratio Nuwellis, Inc. NUWE|aethlonmedical.com (AEMD) - Market Cap to Future Revenue Ratio|ASXC - Price-to-Projected Revenue Ratio|AVGR (Avinger Inc.) - Market Cap to Projected Revenue|BSGM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cutera Inc (CUTR)|Forward Price-to-Revenue Multiple KNW|NARI (inarimedical.com) - Price to Expected Revenue Ratio|Forward P/S Multiple NVRO|Market Cap to Expected Sales Ratio reshapelifesciences.com|Forward P/S Multiple SILK (Silk Road Medical Inc.)
